The CoTras Vision system is feasible and safe in patients with stroke. Most patients had a high degree of motivation to use the system and did not experience severe adverse events. Further studies are needed to confirm its usefulness in stroke patients with visual field defects and hemineglect symptoms. Furthermore, a large, well-designed, randomized controlled trial will be needed to confirm the treatment effect of the CoTras Vision system.
Keyphrases
- randomized controlled trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- atrial fibrillation
- prognostic factors
- peritoneal dialysis
- systematic review
- early onset
- physical activity
- depressive symptoms
- smoking cessation
- blood brain barrier
- cerebral ischemia
- clinical decision support
- electronic health record
- sleep quality